• Bone Biologics postponed its 2026 annual shareholder meeting to Sept. 28 from Aug. 11.
• Delay allows time for investors to review proxy materials tied to an added proposal in a forthcoming definitive proxy filing.
• New record date set for Aug. 6; meeting scheduled for 11:30 a.m. ET at the company’s Burlington, Massachusetts offices.
• Deadline for shareholder director nominations or other proposals reset to July 26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033586), on July 16, 2026, and is solely responsible for the information contained therein.